Related Experiment Video
Updated: Mar 22, 2026
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
Antifungal activity of the piroctone olamine in experimental intra-abdominal candidiasis
Fabíola Maria Marques do Couto1, Silene Carneiro do Nascimento2, Silvio Francisco Pereira Júnior1
1Department of Mycology, Federal University of Pernambuco (UFPE), Av. da Engenharia, s/n, Cidade Universitária, Recife, PE CEP 50740-550 Brazil.
Abstract:
This work aimed to evaluate the antifungal activity of piroctone olamine in the treatment of intra-abdominal candidiasis in an experimental model using Swiss mice. The mice (n = 6) were infected by intraperitoneal injection of 0.2 ml of C. albicans (10(7)cells/ml in saline). The animals were observed daily for clinical signs and mortality for 14 days. The treatment with piroctone olamine (0.5 mg/kg) was performed 72 h after infection by intraperitoneal administration. For comparison, a group of animals (n = 6) was treated with amphotericin B (0.5 mg/kg). The mycological diagnosis was made by collecting the liver, spleen and kidneys. Data regarding the fungal growth and mortality were analyzed statistically by Student's t test and analysis of variance (ANOVA), with level of significance set at P < 0.05. The difference in fungal growth scoring between the control group and the treatment groups (piroctone olamine and amphotericin B) was statistically significant (P < 0.05). The difference in fungal growth scoring between the treatment groups (piroctone olamine and amphotericin B) was not statistically significant (P < 0.05).
Insights
Piroctone olamine demonstrated significant antifungal activity against intra-abdominal candidiasis in mice, comparable to amphotericin B. This study highlights its potential as an effective treatment for fungal infections.
Area of Science:
- Medical Mycology
- Pharmacology
- Infectious Diseases
Background:
- Intra-abdominal candidiasis poses a significant clinical challenge.
- Limited treatment options necessitate the exploration of novel antifungal agents.
- Piroctone olamine is a known antifungal compound with potential therapeutic applications.
Purpose of the Study:
- To evaluate the efficacy of piroctone olamine in treating experimental intra-abdominal candidiasis.
- To compare the antifungal activity of piroctone olamine with amphotericin B, a standard antifungal drug.
- To assess the impact of piroctone olamine on fungal burden in key organs.
Main Methods:
- An experimental model of intra-abdominal candidiasis was established in Swiss mice using Candida albicans.
- Mice were treated with piroctone olamine or amphotericin B via intraperitoneal administration.
- Fungal growth in the liver, spleen, and kidneys was assessed, and mortality rates were recorded.
- Statistical analysis using Student's t-test and ANOVA was performed to determine significance (P < 0.05).
Main Results:
- Both piroctone olamine and amphotericin B significantly reduced fungal growth compared to the control group.
- There was no statistically significant difference in fungal growth reduction between piroctone olamine and amphotericin B treatments.
- The study observed significant differences in fungal growth scoring between control and treatment groups (P < 0.05).
Conclusions:
- Piroctone olamine exhibits significant antifungal activity against Candida albicans in an experimental model of intra-abdominal candidiasis.
- Its efficacy is comparable to that of amphotericin B, suggesting its potential as an alternative antifungal therapy.
- Further research is warranted to explore the clinical utility of piroctone olamine for candidiasis treatment.
